Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

NCT06175000 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Primary Central Nervous System Lymphoma

Interventions

PROCEDURE: Cognitive Assessment
BIOLOGICAL: Obinutuzumab
OTHER: Quality of Life Assessment

Sponsor

Providence Health & Services